RecruitingPHASE1, PHASE2NCT06090539

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Studying Non-Hodgkin lymphoma

Last synced from ClinicalTrials.gov May 14, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Bristol-Myers Squibb
Principal Investigator: Bristol-Myers Squibb
Bristol-Myers Squibb
Intervention: BMS-986458(drug)
Enrollment: 308 target
Eligibility: 18 years · All sexes
Timeline: 2023 – 2028

Study locations (30)

Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Local Institution - 0068, Jacksonville, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Local Institution - 0014, Fairway, Kansas, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota, United States
Local Institution - 0124, Omaha, Nebraska, United States
Local Institution - 0047, Lake Success, New York, United States
Local Institution - 0037, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Local Institution - 0040, Pittsburgh, Pennsylvania, United States
Local Institution - 0045, Providence, Rhode Island, United States
Local Institution - 0024, Milwaukee, Wisconsin, United States
Local Institution - 0118, Antofagasta, AN, Chile
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06090539 on ClinicalTrials.gov

Other trials for Non-Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Non-Hodgkin lymphoma →

← Back to all trials